

## Claims

1. An ophthalmic solution comprising latanoprost as an active ingredient, wherein latanoprost is stabilized to be stored at room temperature by at least one means selected from the following 1) and 2);
  - 1) adjusting pH of the solution to 5.0 to 6.25 and
  - 2) adding  $\epsilon$ -aminocaproic acid to the solution.
2. The ophthalmic solution as claimed in claim 1, wherein a concentration of latanoprost is 0.001 to 0.01% (W/V).
3. The ophthalmic solution as claimed in claim 1, wherein a concentration of latanoprost is 0.001 to 0.01% (W/V), and a concentration of  $\epsilon$ -aminocaproic acid is 0.1 to 2% (W/V).
4. The ophthalmic solution as claimed in claim 3, wherein the concentration of latanoprost is 0.005% (W/V), and the concentration of  $\epsilon$ -aminocaproic acid is 1% (W/V).